21 CFR Part 211 Current Good Manufacturing Practice for Pharmaceutical Manufacturers

21 CFR Part 211 applies to finished pharmaceutical products — prescription drugs, OTC drugs, and drug products subject to the FD&C Act. 21 CFR Part 111 applies to dietary supplements regulated under DSHEA. Part 211 imposes significantly more rigorous requirements, particularly around validation (equipment, process, cleaning, and computer validation), laboratory controls (reference standards, stability programs), and batch record requirements. Supplement companies expanding into OTC drug manufacturing must step up to full Part 211 compliance — a transition Affinity QMS supports without requiring a system migration.

Yes. Any company that manufactures finished OTC drug products — whether under an OTC monograph, NDA, or ANDA — is subject to 21 CFR Part 211 cGMP requirements. This applies to companies manufacturing branded OTC products, generic OTC drugs, and private-label OTC formulations for retail chains. OTC drug manufacturers must maintain Part 211-compliant systems for document control, batch records, process validation, laboratory controls, complaint handling, and CAPA. The FDA's CDER conducts inspections of OTC drug facilities under the same framework as prescription drug facilities.

A Pre-Approval Inspection (PAI) is an FDA inspection triggered by an NDA or ANDA submission to verify that the manufacturing facility and processes described in the application match actual manufacturing conditions and that the facility can consistently produce drug product to the submitted specifications. FDA investigators review: process validation records, master batch records and executed batch records, laboratory controls and out-of-specification investigation records, CAPA systems, and the overall quality system infrastructure. A PAI finding of Official Action Indicated (OAI) will delay or prevent product approval. Affinity QMS organizes all of this documentation in the structure FDA investigators expect to see.

Affinity QMS supports pharmaceutical batch records at two levels: Master Production and Control Records (MPCR) that serve as the template for each product, and executed Batch Production Records (BPR) created from the MPCR for each batch manufactured. MPCRs are maintained under document control with version control and change control workflows. Executed BPRs capture in-process data, equipment used, in-process test results, deviation linkages, and electronic signatures at each critical step. The complete batch record — including all attachments — is retrievable on demand for FDA investigators and is stored with a tamper-evident audit trail.

503B outsourcing facilities registered with the FDA under Section 503B of the FD&C Act are required to comply with full 21 CFR Part 211 cGMP requirements. In addition to Part 211, 503B facilities producing sterile drug products must comply with USP Chapter 797 (sterile compounding) and USP Chapter 800 (hazardous drug handling). FDA conducts regular inspections of 503B facilities and has issued numerous warning letters to facilities with deficient batch records, inadequate environmental monitoring programs, and insufficient CAPA systems. Affinity QMS provides the Part 211 QMS infrastructure that 503B facilities need, with module extensions available for USP 797/800-specific documentation requirements.

Yes. The Affinity QMS Validation Protocol Engine auto-generates IQ (Installation Qualification), OQ (Operational Qualification), and PQ (Performance Qualification) protocols for manufacturing equipment, cleaning processes, analytical methods, and computer systems. For 503B facilities producing sterile drug products, the engine generates protocols aligned to USP 797 environmental monitoring and process validation requirements. All generated protocols are linked to the relevant Master Production Record and can be executed and approved electronically within the platform. This eliminates the need to purchase a separate validation package or hire validation consultants for routine equipment qualification activities.